- Home
- RIGL vs EOI Comparison
RIGL vs EOI Comparison
Compare RIGL & EOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | EOI |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 817.2M |
| IPO Year | 2000 | 2004 |
Fundamental Metrics
Financial Performance| Metric | RIGL | EOI |
|---|---|---|
| Price | $49.17 | $20.20 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $63.00 | N/A |
| AVG Volume (30 Days) | ★ 194.5K | 70.0K |
| Earning Date | 11-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $21.95 | N/A |
| P/E Ratio | $36.91 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $18.04 |
| 52 Week High | $52.24 | $21.09 |
Technical Indicators
Market Signals| Indicator | RIGL | EOI |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 60.87 |
| Support Level | $33.93 | $20.12 |
| Resistance Level | $49.50 | $20.70 |
| Average True Range (ATR) | 1.86 | 0.23 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 74.01 | 99.19 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.